
News|Articles|November 5, 2014
Vaccine Strategies in Follicular Lymphoma
Author(s)Joshua Brody, MD
Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma.
Advertisement
Clinical Pearls
Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses vaccine strategies in follicular lymphoma. Brody presented on this topic at the 2014 Chemotherapy Foundation Symposium.
- First generations of lymphoma vaccines looked promising, but were not efficacious enough to become standard therapies.
- New lymphoma vaccines take a more holistic perspective targeting any tumor-specific or tumor-associated antigens.
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5



















